BFRI · Biofrontera Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $46.17M | $41.71MG | $37.32M | $34.07M | $28.67M | $24.1M | $18.85M | |
| -$2.36M | — | — | -$468K | -$195K | -$344K | -$2.87M | |
| $2.99M | $3.72M | $2.09M | $77K | — | — | — | |
| $21.98M | $22.87M | $16.28M | $18.49M | — | — | — | |
| $39.19M | $37.75M | $33.79M | $38.98M | $35.14M | $36.51M | $17.71M | |
| $25K | — | $329K | $418K | $418K | $418K | $418K | |
| — | $138K | $421K | $600K | — | — | — | |
| — | — | — | — | — | $752K | $1.13M | |
| — | $53.05M | $54.53M | $56.75M | $47.26M | $49.3M | $28.46M | |
| $52.74M | $53.05M | $54.53M | $56.75M | — | — | — | |
| -$6.57M | -$11.35M | -$17.21M | -$22.68M | -$18.58M | -$25.2M | -$9.61M | |
| — | -27.21% | -46.11% | -66.56% | -64.8% | -104.57% | -50.96% | |
| — | -$11.21M | -$16.79M | -$22.08M | — | — | — | |
| — | — | — | $220K | $12K | $344K | $2.87M | |
| — | — | $71K | $132K | $165K | $16K | $28K | |
| $229K | $837K | -$527K | $2.56M | $17.97M | -$12.46M | -$1.32M | |
| — | $2000 | -$14K | -$7.42M | $1.75M | — | — | |
| — | $2000 | -$14K | -$7.42M | $1.75M | — | — | |
| -$6.34M | -$10.51M | -$17.74M | -$20.12M | -$608K | -$37.66M | -$10.92M | |
| — | $25K | $22K | $14K | $32K | $56K | $64K | |
| -$6.37M | -$10.54M | -$17.76M | -$20.13M | -$640K | -$37.71M | -$10.99M | |
| — | -25.26% | -47.58% | -59.09% | -2.23% | -156.49% | -58.29% | |
| — | — | — | — | — | -$37.71M | -$10.99M | |
| USD/shares | -$0.46 | -$1.04 | -$3.22 | -$13.02 | -$0.61 | -$85.60 | — |
| USD/shares | -$0.46 | -$1.04 | -$3.22 | -$13.02 | -$0.61 | — | — |
| shares | — | 10.17M | 5.52M | 1.55M | 1.06M | 440.41K | 1.15M |
| shares | — | 10.17M | 5.52M | 1.55M | 1.06M | 440.41M | 1.15M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 39 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2021 | FY2020 |
|---|---|---|---|---|
| Second A and R Ameluz LSA | $150,000,000 | — | — | — |
| Ameluz LSA | — | $150,000,000 | — | — |
| Revenues Related Party | — | — | $57,000 | $62,000 |
| Product | — | — | $24,043,000 | $18,787,000 |